trimipramine

Your question

Ask in your own words. Each question is answered independently.

Explore sample questions

Select a question to fill the editor, then ask it or make it your own.

DrugCentral answer

Your answer will appear here. Open linked drug cards in a new tab to explore the source details.

About Ask DrugCentral

Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.

General architecture

Ask a questionThe browser sends your question to the same-origin Django chat API.
Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.

Using the assistant

Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.

Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.

Dose	Unit	Route
0.15	g	O
0.15	g	P

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	11.31 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	40 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	16 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	16 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.05 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	23 hours	Lombardo F, Berellini G, Obach RS

Property	Description	Value	Confidence	Similarity
kinase-safety-class	ACVR2A,ACVR2B,AKT1,AKT2,AKT3,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK2,JAK3,MAP3K7,MAPK10,MAPK12,MAPK7,MAPKAPK2,MET,NTRK2,PDK2,PDK4,PDPK1,PIM2,PRKDC,SIK2,SIK3,STK33,TEK,TGFBR1,TTK	41
kinase-selectivity-class	PDK4	1
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
pld-class	Phospholipidosis risk class (1 = positive, 0 = negative)	1	High	1

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Deafness transitory	127.67	17.60	28	4786	2015	90621618
Functional gastrointestinal disorder	102.43	17.60	28	4786	5034	90618599
Abnormal loss of weight	94.16	17.60	28	4786	6795	90616838
Coma	89.98	17.60	53	4761	72579	90551054
Gastrointestinal pain	80.50	17.60	28	4786	11178	90612455
Traumatic coma	76.62	17.60	11	4803	61	90623572
Feeding disorder	68.33	17.60	28	4786	17484	90606149
Musculoskeletal disorder	59.29	17.60	27	4787	21742	90601891
Pharyngitis	59.08	17.60	27	4787	21920	90601713
Eating disorder	52.76	17.60	27	4787	28046	90595587
Suicide attempt	51.63	17.60	38	4776	75361	90548272
Pneumonia aspiration	50.99	17.60	30	4784	40910	90582723
Somnolence	49.21	17.60	58	4756	209026	90414607
Hypophagia	49.18	17.60	28	4786	35909	90587724
Toxicity to various agents	49.06	17.60	68	4746	287778	90335855
Atrial septal defect	45.69	17.60	17	4797	8217	90615416
Drug interaction	45.15	17.60	64	4750	276389	90347244
Parachute mitral valve	43.02	17.60	7	4807	97	90623536
Electrocardiogram QT prolonged	39.71	17.60	32	4782	72424	90551209
Drug abuse	36.14	17.60	32	4782	82315	90541318
Coarctation of the aorta	35.93	17.60	8	4806	616	90623017
Congenital tricuspid valve incompetence	33.84	17.60	6	4808	142	90623491
Ear infection	32.39	17.60	28	4786	69747	90553886
Deafness	32.03	17.60	18	4796	22496	90601137
Polyglandular autoimmune syndrome type II	31.97	17.60	5	4809	53	90623580
Patent ductus arteriosus	31.21	17.60	11	4803	4558	90619075
Victim of sexual abuse	29.76	17.60	7	4807	688	90622945
Product prescribing error	27.18	17.60	18	4796	30127	90593506
Miosis	26.56	17.60	12	4802	9472	90614161
Ventricular septal defect	25.80	17.60	10	4804	5397	90618236
Paranasal sinus inflammation	25.09	17.60	6	4808	633	90623000
Gastrooesophageal reflux disease	24.91	17.60	37	4777	166300	90457333
Apathy	24.82	17.60	12	4802	11028	90612605
Sinobronchitis	24.53	17.60	6	4808	695	90622938
Incorrect dosage administered	23.87	17.60	8	4806	2852	90620781
Underdose	23.70	17.60	21	4793	53996	90569637
Intentional overdose	23.65	17.60	27	4787	93807	90529826
Prescription drug used without a prescription	22.86	17.60	8	4806	3247	90620386
Disturbance in attention	22.05	17.60	19	4795	47090	90576543
Hypertensive crisis	22.04	17.60	13	4801	17771	90605862
Adverse drug reaction	22.00	17.60	29	4785	116672	90506961
Shoulder arthroplasty	20.93	17.60	8	4806	4158	90619475
Product monitoring error	20.26	17.60	8	4806	4536	90619097
Depressed level of consciousness	20.15	17.60	22	4792	72762	90550871
Foramen magnum stenosis	19.96	17.60	4	4810	185	90623448
Cancer fatigue	19.80	17.60	4	4810	193	90623440
Dizziness	19.45	17.60	72	4742	589212	90034421
Junctional ectopic tachycardia	19.34	17.60	4	4810	217	90623416
Leukopenia	18.94	17.60	25	4789	100685	90522948
Haematoma	18.78	17.60	16	4798	39032	90584601
Tachycardia	18.00	17.60	31	4783	157642	90465991
Loss of consciousness	17.91	17.60	29	4785	140209	90483424
Foot operation	17.90	17.60	9	4805	8992	90614641
Post laminectomy syndrome	17.61	17.60	4	4810	337	90623296

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Prescription drug used without a prescription	103.59	34.61	23	1456	2707	42617149
Drug interaction	71.96	34.61	65	1414	266934	42352922
Brain oedema	70.45	34.61	25	1454	16302	42603554
Toxicity to various agents	70.14	34.61	60	1419	229076	42390780
Restlessness	59.55	34.61	26	1453	29223	42590633
Testicular seminoma (pure)	48.08	34.61	8	1471	201	42619655
Pulmonary oedema	47.46	34.61	27	1452	53245	42566611
Suicide attempt	42.77	34.61	24	1455	46076	42573780
Screaming	35.12	34.61	9	1470	1938	42617918

Ask DrugCentral

Your question

DrugCentral answer

About Ask DrugCentral

General architecture

Using the assistant

trimipramine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Prescription drug used without a prescription	113.85	18.99	30	5019	5466	110578784
Toxicity to various agents	110.26	18.99	122	4927	480433	110103817
Drug interaction	109.66	18.99	124	4925	500059	110084191
Coma	105.19	18.99	66	4983	117803	110466447
Traumatic coma	68.68	18.99	10	5039	74	110584176
Suicide attempt	65.92	18.99	47	5002	103347	110480903
Deafness transitory	64.98	18.99	14	5035	1079	110583171
Brain oedema	63.02	18.99	30	5019	31068	110553182
Somnolence	55.42	18.99	68	4981	297381	110286869
Drug abuse	54.86	18.99	53	4996	177358	110406892
Testicular seminoma (pure)	47.43	18.99	8	5041	164	110584086
Pneumonia aspiration	47.37	18.99	35	5014	81198	110503052
Intentional overdose	43.63	18.99	41	5008	132460	110451790
Functional gastrointestinal disorder	41.26	18.99	14	5035	6035	110578215
Restlessness	36.81	18.99	26	5023	56233	110528017
Victim of sexual abuse	32.58	18.99	7	5042	532	110583718
Miosis	32.13	18.99	17	5032	21966	110562284
Gastrointestinal pain	32.10	18.99	14	5035	11846	110572404
Apathy	30.87	18.99	15	5034	16224	110568026
Abnormal loss of weight	30.69	18.99	13	5036	10244	110574006
Gastrooesophageal reflux disease	30.05	18.99	39	5010	179937	110404313
Shoulder arthroplasty	27.18	18.99	9	5040	3598	110580652
Electrocardiogram QT prolonged	27.16	18.99	29	5020	108931	110475319
Depressed level of consciousness	26.44	18.99	29	5020	112249	110472001
Deafness	26.43	18.99	16	5033	26693	110557557
Underdose	25.51	18.99	22	5027	63532	110520718
Completed suicide	25.18	18.99	42	5007	242339	110341911
Screaming	24.52	18.99	9	5040	4872	110579378
Foot operation	24.34	18.99	10	5039	7303	110576947
Feeding disorder	24.29	18.99	14	5035	21348	110562902
Eyelid bleeding	23.90	18.99	4	5045	78	110584172
Abdominal pain lower	23.85	18.99	17	5032	37266	110546984
Pulmonary oedema	23.70	18.99	26	5023	100633	110483617
Aggression	22.76	18.99	20	5029	59190	110525060
Incorrect dosage administered	22.59	18.99	8	5041	3910	110580340
Hypertensive crisis	22.58	18.99	14	5035	24358	110559892
Loss of consciousness	21.71	18.99	35	5014	196271	110387979
Product prescribing error	21.07	18.99	18	5031	51313	110532937
Musculoskeletal disorder	20.95	18.99	13	5036	22651	110561599
General physical health deterioration	20.77	18.99	54	4995	425241	110159009
Pharyngitis	19.73	18.99	13	5036	25085	110559165
Polyglandular autoimmune syndrome type II	19.00	18.99	3	5046	40	110584210

Source	Code	Description
ATC	N06AA06	NERVOUS SYSTEM PSYCHOANALEPTICS ANTIDEPRESSANTS Non-selective monoamine reuptake inhibitors
MeSH PA	D000928	Antidepressive Agents
MeSH PA	D000929	Antidepressive Agents, Tricyclic
MeSH PA	D011619	Psychotropic Drugs
MeSH PA	D014179	Neurotransmitter Uptake Inhibitors
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018663	Adrenergic Agents
MeSH PA	D018759	Adrenergic Uptake Inhibitors
MeSH PA	D049990	Membrane Transport Modulators
FDA EPC	N0000175752	Tricyclic Antidepressant
CHEBI has role	CHEBI:35469	antidepressant
CHEBI has role	CHEBI:35474	anxiolytic drug
CHEBI has role	CHEBI:35476	antipsychotic agent
CHEBI has role	CHEBI:35703	xenobiotic
CHEBI has role	CHEBI:78298	environmental contaminant

Disease	Relation	SNOMED_ID	DOID
Depressive disorder	indication	35489007
Neuralgia	off-label use	16269008
Ocular hypertension	contraindication	4210003	DOID:9282
Suicidal thoughts	contraindication	6471006
Alcoholism	contraindication	7200002
Bipolar disorder	contraindication	13746004	DOID:3312
Electroconvulsive therapy	contraindication	23835007
Hyperthyroidism	contraindication	34486009	DOID:7998
Conduction disorder of the heart	contraindication	44808001
Disorder of cardiovascular system	contraindication	49601007	DOID:1287
Schizophrenia	contraindication	58214004	DOID:5419
Epilepsy	contraindication	84757009	DOID:1826
Kidney disease	contraindication	90708001	DOID:557
Cerebrovascular accident	contraindication	230690007
Mania	contraindication	231494001
Hypomania	contraindication	231496004
Disease of liver	contraindication	235856003	DOID:409
Benign prostatic hyperplasia	contraindication	266569009
Retention of urine	contraindication	267064002
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Neutropenic disorder	contraindication	303011007	DOID:1227
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Disorder of coronary artery	contraindication	414024009
Myocardial infarction in recovery phase	contraindication	418044006

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN	INHIBITOR	Ki	6.83	PDSP	IUPHAR
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN	INHIBITOR	Ki	5.61	IUPHAR	CHEMBL
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN	INHIBITOR	Ki	5.42	PDSP	IUPHAR
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN	ANTAGONIST	Ki	8.85	PDSP
Voltage-dependent N-type calcium channel subunit alpha-1B	Ion channel	Q00975	CAC1B_HUMAN		IC50	4.96	CHEMBL
Solute carrier family 22 member 1	Transporter	O15245	S22A1_HUMAN		IC50	4.56	CHEMBL

ID	Source
4019962	VUID
N0000148047	NUI
D00394	KEGG_DRUG
521-78-8	SECONDARY_CAS_RN
4018060	VANDF
4019962	VANDF
C0041056	UMLSCUI
CHEBI:9738	CHEBI
CHEMBL644	ChEMBL_ID
DB00726	DRUGBANK_ID
CHEMBL1200948	ChEMBL_ID
D014299	MESH_DESCRIPTOR_UI
5584	PUBCHEM_CID
7317	IUPHAR_LIGAND_ID
1414	INN_ID
6S082C9NDT	UNII
10834	RXNORM
2164	MMSL
5636	MMSL
72541	MMSL
d00873	MMSL
001507	NDDF
004605	NDDF
005363	NDDF
373550009	SNOMEDCT_US
734496007	SNOMEDCT_US
87831009	SNOMEDCT_US
90426002	SNOMEDCT_US
25332-13-2	SECONDARY_CAS_RN
6S082C9NDT	INXIGHT DRUGS

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Trimipramine	HUMAN PRESCRIPTION DRUG LABEL	1	51991-944	CAPSULE	25 mg	ORAL	ANDA	22 sections
Trimipramine	HUMAN PRESCRIPTION DRUG LABEL	1	51991-945	CAPSULE	50 mg	ORAL	ANDA	22 sections
Trimipramine	HUMAN PRESCRIPTION DRUG LABEL	1	51991-946	CAPSULE	100 mg	ORAL	ANDA	22 sections
Trimipramine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	64850-850	CAPSULE	25 mg	ORAL	ANDA	22 sections
Trimipramine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	64850-851	CAPSULE	50 mg	ORAL	ANDA	22 sections
Trimipramine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	64850-852	CAPSULE	100 mg	ORAL	ANDA	22 sections
Trimipramine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	72162-2061	CAPSULE	25 mg	ORAL	ANDA	22 sections
Trimipramine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	72162-2062	CAPSULE	50 mg	ORAL	ANDA	22 sections
Trimipramine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	72162-2063	CAPSULE	100 mg	ORAL	ANDA	22 sections

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.92	Basic
pKa2	5.01	Basic